NCT00587314
The Effect of Ablation Therapy on Barrett's Esophagus
Enrolling by Invitation
Not specifiedAges 18–90ObservationalMayo ClinicInvestigator-initiated
~600 participants
Updated 2026-03-11 on ClinicalTrials.gov
What's tested:Biopsy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Response to treatment
Measured over at time of surveillance intervals
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Cadman Leggett, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients who have had or qualify for ablation therapy for treatment of their barrett's esophagus with high grade dysplasia or early esophageal adenocarcinoma
Ability to provide informed consent
Exclusion
Eastern Cooperative Oncology Group performance status 3 or 4
Inability to tolerate endoscopic procedures
Pregnancy: Females of child-bearing age will be screened with pregnancy test.
What this trial measures
- Response to treatmentat time of surveillance intervals
presence of persistent or recurrence of barrett's esophagus and/or dysplasia